J.-L. Canon
About
In The Last Decade
J.-L. Canon
15 papers receiving 333 citations
Peers
Comparison fields: 5 of 47
- Oncology 288
- Surgery 122
- Pulmonary and Respiratory Medicine 105
- Molecular Biology 30
- Hepatology 30
Countries citing papers authored by J.-L. Canon
This map shows the geographic impact of J.-L. Canon's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J.-L. Canon with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J.-L. Canon more than expected).
Fields of papers citing papers by J.-L. Canon
This network shows the impact of papers produced by J.-L. Canon. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J.-L. Canon. The network helps show where J.-L. Canon may publish in the future.
Co-authorship network of co-authors of J.-L. Canon
This figure shows the co-authorship network connecting the top 25 collaborators of J.-L. Canon. A scholar is included among the top collaborators of J.-L. Canon based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with J.-L. Canon. J.-L. Canon is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 2 | |
| 2 | 8 | |
| 3 | 3 | |
| 4 | 3 | |
| 5 | 39 | |
| 6 | 19 | |
| 7 | 2 | |
| 8 | 128 | |
| 9 | 0 | |
| 10 | 106 | |
| 11 | Sequential administration of epirubicin and paclitaxel for advanced breast cancer. A phase I randomised trial. | 4 |
| 12 | 9 | |
| 13 | 1 | |
| 14 | 6 | |
| 15 | Importance of 5-fluorouracil dose-intensity in a double randomised trial on adjuvant portal and systemic chemotherapy for Dukes B2 and C colorectal cancer. | 3 |
| 16 | 1 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.